This was a retrospective analysis of patients with HER2-negative MBC who received treatment with bevacizumab (Fritz Hoffmann-La Roche, Basel, Switzerland; 10 mg/kg on days 1 and 15, every 28 days) plus paclitaxel (Bristol-Myers Squibb, New York, NY, USA; 80 mg/m2 on days 1, 8, and 15, every 28 days) as first-line therapy, second-line therapy, or subsequent lines, including those who received bevacizumab continuation therapy after completion of paclitaxel, at La Paz University Hospital between August 2007 and October 2012. All analyses were approved by the local ethics committee.
Bevacizumab
Manufactured by Bristol-Myers Squibb
Sourced in United States, Brazil
Bevacizumab is a monoclonal antibody that binds to and inhibits the vascular endothelial growth factor (VEGF). It is used in the development and production of various pharmaceutical products.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using bevacizumab
1
Bevacizumab Plus Paclitaxel in HER2-Negative MBC
2
Analytical characterization of anti-cancer agents
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Twenty-one anti-cancer agents tested in this study (Table SI ) were dissolved in dimethyl sulfoxide (final concentration; 20 mM) and stored at −80°C until use. The purity and integrity of the agents were measured using ultra-performance liquid chromatography-mass spectrometry (Waters Corporation) as follows: a 1-µl injection volume, a Waters CORTECS C18 column (particle size: 1.6 µm; column size: 2.1×50 mm; Waters Corporation), linear aqueous acetonitrile (MeCN) gradient containing 0.1% formic acid (5–90% MeCN, 1.6 min; flow rate, 1 ml/min, 40°C), and the components of the significant ultraviolet adsorption peaks were identified using mass spectrometry (Table SI ).
Cetuximab and bevacizumab were obtained from Bristol Myers Squibb and Merck & Co., respectively. Blinatumomab was provided by Amgen.
Cetuximab and bevacizumab were obtained from Bristol Myers Squibb and Merck & Co., respectively. Blinatumomab was provided by Amgen.
3
Comparison of Bevacizumab and Mitomycin C in Glaucoma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
GFS was performed by a single surgeon on the right eye only. The surgeries were performed with the animals under general anesthesia by intramuscular injection of ketamine 50 mg/mL and xylazine 2%. The animals were randomly allocated into three groups according to the medications used during the surgery:
Group A: bevacizumab (Avastin ® , Genentech, San Francisco, CA, USA). Subconjunctival injection using a 27-gauge needle (1.25-0.05 mL), adjacent to the site of the surgery at the end of the procedure.
Group B: MMC (Mitocin ® , Bristol-Myers Squibb, São Paulo, SP, Brazil) (0.2 mg/mL) soaked in a semilunar 8-mm diameter sponge (25.12 mm 2 area), placed between the Tenon capsule and sclera for 3 min, followed by continuous irrigation with 20 mL of balanced salt solution and subconjunctival injection of bevacizumab as described above.
Group C: MMC application alone, as previously described.
Group A: bevacizumab (Avastin ® , Genentech, San Francisco, CA, USA). Subconjunctival injection using a 27-gauge needle (1.25-0.05 mL), adjacent to the site of the surgery at the end of the procedure.
Group B: MMC (Mitocin ® , Bristol-Myers Squibb, São Paulo, SP, Brazil) (0.2 mg/mL) soaked in a semilunar 8-mm diameter sponge (25.12 mm 2 area), placed between the Tenon capsule and sclera for 3 min, followed by continuous irrigation with 20 mL of balanced salt solution and subconjunctival injection of bevacizumab as described above.
Group C: MMC application alone, as previously described.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!